Sagar Lonial, MD, FACP, on Multiple Myeloma Awareness Month
By Sagar Lonial, MD, FACP - March 6, 2023Why is Multiple Myeloma Awareness Month important? Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, shares his thoughts on the matter in this video.
Advertisement
Related Posts
The phase III study included patients who received at least one prior line of therapy.
The researchers sought to assess the utility of MRD outside the context of clinical trials.
Daratumumab in combination with lenalidomide and dexamethasone provided greater OS in most subgroups.
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.